Voices
Pashtoon Kasi: Targeting HER2 in Refractory CRC – Key Takeaways From the MOUNTAINEER Final Analysis
Pashtoon Kasi/X

Pashtoon Kasi: Targeting HER2 in Refractory CRC – Key Takeaways From the MOUNTAINEER Final Analysis

Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope Orange County, shared a post on LinkedIn:

“Published Nature Comms

Tucatinib plus Trastuzumab
Mountaineer regimen

For those patients with
HER2 plus POSITIVE colorectal cancer CRCSM

Some advances are coming for patients with specific types of cancers.
HER2 actionable.”

Title: Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis

Authors: John H. Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz-Josef Lenz, Kristen Ciombor, Elena Elez, David L. Bajor, Chiara Cremolini, Federico Sanchez, Mina Nayeri, Wentao Feng, Mark Bieda, Tanios S. Bekaii-Saab

Read the Full Article.

Pashtoon Kasi: Targeting HER2 in Refractory CRC - Key Takeaways From the MOUNTAINEER Final Analysis

More posts featuring Pashtoon Kasi on OncoDaily.

Adel Kardosh Andrea Cercek Andrew L Coveler Andrew Scott Paulson Chiara Cremolini Christina Wu Christos Fountzilas David L. Bajor Elena Elez Eric van Cutsem Federico Sanchez Heinz Josef Lenz John H Strickler Joleen M. Hubbard Kimmie Ng Kristen Ciombor Mark Bieda Mina Nayeri Pashtoon Murtaza Kasi Salvatore Siena Tanios S Bekaii-Saab Thierry Andre Wentao Feng